SBL
ARCT icon

Sargent Bickham Lagudis’s Arcturus Therapeutics ARCT Stock Holding History

Sargent Bickham Lagudis’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$1.7K Hold
100
– – ﹤0.01% 938
2022
Q3 		$1K Hold
100
– – ﹤0.01% 918
2022
Q2 		$2K Hold
100
– – ﹤0.01% 898
2022
Q1 		$3K Hold
100
– – ﹤0.01% 836
2021
Q4 		$4K Hold
100
– – ﹤0.01% 812
2021
Q3 		$5K Buy
+100
New +$4.48K ﹤0.01% 802

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Sargent Bickham Lagudis's ARCT Position: Q4 2022 in Review

Sargent Bickham Lagudis held its Arcturus Therapeutics (ARCT) position steady in Q4 2022 at 100 shares worth $1.7K. The position accounts for ﹤0.01% of the portfolio, ranked #938.

Sargent Bickham Lagudis first reported a position in ARCT in Q3 2021 and has held it in 6 quarters since. The position peaked at $5K in Q3 2021. 111 funds tracked by Wall St. Rank hold ARCT as of Q4 2022.

  • Sargent Bickham Lagudis held 100 shares of Arcturus Therapeutics worth $1.7K as of Q4 2022.
  • Sargent Bickham Lagudis left its Arcturus Therapeutics share count unchanged in Q4 2022.
  • Arcturus Therapeutics made up ﹤0.01% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #938 holding.
  • Sargent Bickham Lagudis first reported a position in Arcturus Therapeutics in Q3 2021 and has held it in 6 quarters since.
  • Sargent Bickham Lagudis's Arcturus Therapeutics position peaked at $5K in Q3 2021.
  • 111 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.